Product Overview
Thymalin, sometimes spelled timalin, is not a single designed molecule. It is a polypeptide fraction obtained from bovine thymus tissue and then dried, and Generic Peptides offers it in 20 mg and 50 mg vials. That origin explains most of its quirks: because it is an extract rather than a defined sequence, the exact composition varies with the batch, and the laboratory work has centred on two very short fragments, the dipeptides lysine-glutamate and glutamate-tryptophan.
Those two dipeptides, usually written KE and EW, are small enough to pass into a cell and into its nucleus, where they bind particular promoter sequences and shift gene expression. In a model using lipopolysaccharide to provoke human peripheral blood cells, Thymalin and its fragments reduced the synthesis of interleukin-1 beta, interleukin-6 and tumour necrosis factor alpha by a factor of 1.4 to 6.0, which is the mechanistic claim behind the immune positioning.
The clinical record is real but narrow. In a 2021 study of elderly patients with severe COVID-19, 10 mg a day was given intramuscularly for 10 days as part of complex treatment, and the authors reported normalisation of leucocyte, lymphocyte, monocyte and natural killer cell counts. An older geroprotective study followed 266 people over 60 for six to eight years and reported lower mortality in the treated group, but no independent Western group has reproduced it, and no human pharmacokinetics have been published at all.
Dosage Protocol
There is no approved schedule for buyers of research material, and the quantities circulating come from Russian clinical literature rather than from a label. The table sets out those literature figures next to the dilution arithmetic, and the hospital vial in the papers was a 10 mg presentation.
| Literature course | 5-10 mg intramuscularly each day for 5-10 days, then observation |
| COVID-19 study | 10 mg daily for 10 days in elderly patients, used inside a broader treatment plan |
| Route | Intramuscular in the clinical literature; water for injection or bacteriostatic water as the solvent |
| 20 mg plus 2 ml | Gives 10 mg/ml, where a 10 unit pull holds 1 mg |
| 50 mg plus 5 ml | Gives the same 10 mg/ml and the same 1 mg pull |
| 50 mg plus 2 ml | Gives 25 mg/ml and a 2.5 mg pull at 10 units |
| 20 mg plus 4 ml | Gives 5 mg/ml, so 10 units carries 500 mcg |
| Female | No separate protocol is described in the sources checked |
Storage follows the peptide pattern: the dry cake at 2-8 C away from light, the solution also cold, and no freezing at any point. One caution belongs in this section rather than further down. The quantities in the Russian papers were measured with a 10 mg hospital vial, while the fills sold here are 20 mg and 50 mg, so a research calculation has to be made from the concentration in the syringe and not from the size of the bottle.
Suggested Protocols
Nothing in the sources runs Thymalin together with another product from this catalogue in a controlled way, so the groupings below are navigation aids. They separate the immune compounds, the longevity pairing that Russian publications do describe, and the peptides compared with it in the same literature.
What to Expect
- Cytokine suppression in the laboratory. In the provoked blood cell model, Thymalin and the KE and EW fragments cut interleukin-1 beta, interleukin-6 and tumour necrosis factor alpha production by 1.4 to 6.0 times, which is a measured effect rather than a testimonial.
- Action inside the nucleus. The short peptides enter the cell and the nucleus, bind defined promoter motifs, with GGAG favoured by EW and GCGC by KE, and modulate gene expression from there.
- Immune counts in a small clinical setting. The elderly COVID-19 study reported normalised leucocyte, lymphocyte, monocyte and natural killer cell numbers when 10 mg daily was added to complex care.
- A geroprotective signal that has not been repeated. The 266 person study over six to eight years reported lower mortality, and no independent Western team has reproduced that result.
- Different from a synthetic peptide. Because this is a tissue extract, its composition is a mixture, while Thymosin Alpha-1 is a single chain with a published sequence, and the two are not interchangeable.
- No pharmacokinetics at all. A published human absorption and clearance profile does not exist, so nothing can be said about accumulation or about how long one dose lasts.
Side Effects and Management
No modern safety study covers the quantities sold here, and the rows below combine what the older literature mentions with the ordinary consequences of injecting a protein-derived material.
Post-Cycle Therapy
This material has no steroidal action, so a post-cycle protocol would be an invention. It does not suppress the gonadal axis, does not aromatise and does not reduce sperm production, and the recovery drugs used after an anabolic course have nothing to act on.
For athletes the position is the same as with the other immune peptides here. Thymalin is not named on the prohibited list, and because it is an unapproved substance outside Russia it can be caught by the general category for non-approved agents, so the absence of a line is not an all-clear. See the synthetic alternative Thymosin Alpha-1 for the version with a defined sequence.
